• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • One-Alpha
    / Dexcel

    Active Ingredient
    Alfacalcidol 0.25 mcg

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    10, 30, 100

    full basket chart


    See prescribing information for full details.


    Renal bone disease, hypothyroidism, rickets and osteomalacia, osteoporosis, primary and tertiary hyperparathyroidism, neonatal hypocalcemia.


    Not to be administered in the presence of plasma calcium levels above 10.8 mg/dl. Evidence of vitamin D toxicity or known hypersensitivity to the effects of vitamin D or any of its analogs.

    Special Precautions

    The intestinal absorption of calcium and phosphate. Serum levels, should be monitored, particularly in patients with renal failure. Should only be prescribed when suitable facilities are available for monitoring calcium levels, renal function and other appropriate biochemical paramenters on a regular basis.

    Side Effects

    Generally relate to hypercalcemia and, in the case of renal impairment, hyperphosphatemia which may be induced by alfacalcidol therapy.

    Drug interactions

    Anticonvulsants, barbiturates, rifampicin. Danazol, digitalis. Mineral oils, cholestyramine, colestipol, sucralfate, aluminum-based antacids. Calcium-containing preparations, thiazides. Magnesium-based antacids, laxatives. Vitamin D or its analogs.

    LEO Pharmaceutical Products Ltd.
    Licence holder